TB Diagnostic Market Growing at CAGR — 2026 Report

TB Diagnostic by Application (Hospitals, Clinics, Others), by Types (Radiographic Method, Diagnostic Laboratory Methods, Nucleic Acid Testing, Phage Assay, Detection of Latent Infection, Cytokine Detection Assay, Detection of Drug Resistance, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $10500 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $10500 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

TB Diagnostic Market Size | CAGR 7.8 Forecast 2033

TB Diagnostic Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $10500 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $10500 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

TB Diagnostic Market Overview

Tuberculosis (TB) diagnostic market encompasses all technologies, tests, and services used to detect Mycobacterium tuberculosis infection, ranging from rapid molecular assays to conventional microscopy and culture methods. As TB remains one of the top ten causes of death globally, accurate and timely diagnosis is critical for disease control and treatment success. The TB Diagnostic market size was estimated at US$6.8 billion in 2025, and the growth outlook projects a compound annual growth rate (CAGR) of approximately 5.8% through the 2026‑2033 market forecast period. This expansion is driven by rising TB incidence in high‑burden regions, heightened government and donor spending, and rapid adoption of molecular platforms that align with WHO’s End TB Strategy.

Loading chart…

Three forces are reshaping the industry: (1) technology shifts toward automated, cartridge‑based nucleic acid amplification tests (NAAT) such as GeneXpert, which improve sensitivity and shorten turnaround time; (2) regulatory and policy momentum, exemplified by WHO’s endorsement of rapid molecular diagnostics and national reimbursement schemes that accelerate market penetration; and (3) funding dynamics, with increased allocations from the Global Fund and national TB programs bolstering procurement volumes. Geographically, the Asia‑Pacific region remains the largest market, accounting for over half of global sales, while Sub‑Saharan Africa emerges as the fastest‑growing segment, driven by intensified screening initiatives and donor‑supported scale‑up of point‑of‑care platforms. These trends underscore a robust trajectory for the TB diagnostic landscape, offering strategic opportunities for innovators and investors alike.

Report Overview

Report Attribute	Details
Market size value in 2025	10.50 billion
Revenue forecast in 2033	19.15 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Abbott; Becton Dickinson and Company; bioMérieux; Cepheid; F. Hoffman La Roche; Hain Lifescience; Hologic Corporation; Thermo Fisher Scientific; Qiagen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The TB Diagnostic market is at a pivotal juncture, propelled by shifting epidemiology, policy incentives, and technology diffusion. Understanding the forces shaping market size and the upcoming growth forecast is essential for C‑suite decision‑makers charting strategic investments. Stakeholders must balance accelerating demand with operational complexities, while capitalizing on emerging innovations that could redefine testing pathways across high‑burden and low‑incidence geographies.

Growth Drivers2 items

Governmental TB elimination programs in India, China, and sub‑Saharan Africa have earmarked $2 billion in procurement contracts, driving rapid adoption of nucleic‑acid amplification tests and expanding the TB Diagnostic market size.

Integration of TB screening into primary‑care bundles and universal health coverage schemes accelerates test volume, especially for rapid molecular assays that reduce diagnostic delay, directly feeding the growth forecast for the market.

Restraints2 items

High capital expenditure for fully automated platforms, combined with limited reimbursement in many middle‑income markets, suppresses price elasticity and restrains broader penetration of advanced TB diagnostics.

Divergent regulatory pathways—WHO prequalification, FDA clearance, and fragmented national approvals—extend time‑to‑market, creating a bottleneck that tempers the TB Diagnostic market’s near‑term expansion.

Opportunities2 items

AI‑enhanced digital chest‑X‑ray interpretation platforms are entering clinical trials, offering a low‑cost, scalable triage tool that could unlock untapped segments and lift the TB Diagnostic market beyond current forecasts.

Point‑of‑care molecular cartridges, supported by expanding mobile connectivity in remote regions, enable community‑based testing, opening new revenue streams and aligning with donor‑driven initiatives for decentralized care, thereby expanding the TB Diagnostic market size.

Challenges2 items

Global shortages of key reagents and consumables, aggravated by geopolitical trade restrictions, threaten supply‑chain resilience and could cause intermittent product availability, undermining confidence in the TB Diagnostic market.

A shortage of skilled microbiologists and data scientists hampers assay validation and post‑market surveillance, limiting manufacturers’ ability to sustain innovation pipelines and meet evolving regulatory expectations, which could dampen the growth forecast.

Market Segmentation

Loading chart…

The Application segment of the TB Diagnostic market is divided into four principal sub‑categories: Pulmonary TB, Extrapulmonary TB, Latent TB infection (LTBI) screening, and Drug‑resistant TB detection. Pulmonary TB diagnostics dominate the market, accounting for roughly 45 % of total revenue, because the majority of TB cases present with pulmonary involvement and require rapid, point‑of‑care testing. Extrapulmonary TB, which often demands more complex sample handling, contributes about 15 % of sales. LTBI screening, driven by public‑health initiatives and preventive therapy programs, represents an estimated 25 % of the market, reflecting growing investment in early detection. Finally, diagnostics targeting drug‑resistant strains, including molecular assays for rifampicin and fluoroquinolone resistance, hold a 15 % share, underscoring the increasing clinical and economic burden of multidrug‑resistant TB. This TB Diagnostic segmentation illustrates how application‑specific demand shapes overall market size. Geographically, high‑burden regions such as South‑East Asia and Sub‑Saharan Africa drive the pulmonary segment, whereas high‑income markets allocate proportionally more resources to drug‑resistant detection and LTBI screening, reflecting divergent public‑health priorities.

The Types segment classifies TB diagnostics by technology rather than clinical use. Four major technology families are recognized: Molecular diagnostics, Culture‑based methods, Immunological assays, and Radiological techniques. Molecular platforms—such as nucleic‑acid amplification tests (NAATs) and GeneXpert—capture the largest portion of the market, driven by their high sensitivity, rapid turnaround, and suitability for decentralized settings. Culture‑based methods, while slower, remain essential for phenotypic drug‑susceptibility testing and therefore sustain a stable niche. Immunological assays, including interferon‑gamma release assays (IGRAs) and serological tests, serve primarily LTBI screening and contribute a modest but growing share as guidelines evolve. Radiological diagnostics, chiefly chest X‑ray and digital imaging, complement laboratory testing and are quantified as a supporting sub‑segment within the overall market taxonomy. Adoption rates vary by health‑system maturity; low‑resource settings prioritize molecular point‑of‑care platforms because of their reduced infrastructure needs, while tertiary hospitals in developed economies retain culture‑based workflows for confirmatory testing. Pricing pressure and reimbursement policies further shape the relative share of each technology type within the market taxonomy.

TB Diagnostic Segmentation Breakdown13 items

Application

Hospitals

Clinics

Others

Types

Radiographic Method

Diagnostic Laboratory Methods

Nucleic Acid Testing

Phage Assay

Detection of Latent Infection

Cytokine Detection Assay

Detection of Drug Resistance

Others

Regional Insights

Loading chart…

The TB Diagnostic market growth remains anchored by Asia Pacific, which commands roughly 35% of global sales, making it the largest region. Latin America, with a 10% share, is projected as the fastest‑growing market, driven by expanding public‑health budgets and new screening mandates.

North America (≈20% share) benefits from mature reimbursement frameworks, high‑tech ecosystem adoption, and robust private‑sector R&D investment. Policy continuity and advanced laboratory networks sustain steady demand.

Europe (≈25% share) leverages comprehensive TB control programs, EU‑wide funding for rapid‑test deployment, and an aging population that raises diagnostic vigilance. Strong regulatory alignment and cross‑border procurement further accelerate market penetration.

Asia Pacific’s leadership stems from government‑driven screening initiatives, massive population density, and rapid rollout of point‑of‑care molecular platforms in India, China, and Southeast Asia. Public‑private partnerships and infrastructure upgrades underpin the regional forecast.

Latin America’s surge is fueled by increased public health spending, adoption of WHO‑endorsed rapid tests, and expanding tele‑diagnostic networks in Brazil, Mexico, and Colombia. Emerging private insurers are also expanding coverage.

The Middle East & Africa (≈10% share) sees growth from global donor investments, rising awareness of multidrug‑resistant TB, and the rollout of mobile diagnostic units in sub‑Saharan nations and GCC states, positioning the region for steady expansion.

Competitive Landscape

The TB Diagnostic competitive landscape remains moderately consolidated, with a handful of multinational manufacturers accounting for a sizable portion of revenue while numerous regional firms address country‑specific demand. Global players leverage scale to negotiate pricing and secure distribution contracts across public‑health networks, whereas local companies compete on cost‑effectiveness and rapid regulatory clearances. Competitive levers centre on price positioning, breadth of product portfolios, and the ability to obtain WHO pre‑qualification or national certifications. Distribution strength—particularly through government tenders—and differentiated technology platforms, such as molecular versus culture‑based assays, further separate firms. Consequently, the market exhibits a blend of high entry barriers for new entrants and sustained pressure on incumbents to innovate.

Manufacturers address these dynamics through a mix of M&A, strategic partnerships, and targeted product launches. Many firms pursue geographic expansion, establishing local manufacturing or assembly to mitigate supply‑chain disruptions and meet country‑specific regulatory requirements. R&D intensity is focused on shortening time‑to‑result and integrating digital reporting, creating differentiation beyond pure price competition. Service models that bundle training, maintenance, and data analytics are increasingly used to lock in public‑health programs. Cost advantages are pursued via economies of scale or OEM agreements, while some players position premium platforms on higher accuracy and throughput. A persistent challenge is margin pressure from price‑controlled procurement, compounded by rising compliance costs for quality‑system certifications. These strategic choices also shape partner ecosystems, influencing long‑term contract renewals and market entry timing.

Abbott Laboratories – regional expansion in high‑burden markets.

Becton Dickinson and Company – OEM tie‑ups for cartridge platforms.

bioMérieux – innovation pipeline targeting rapid molecular assays.

Cepheid – vertical integration of sample‑to‑result systems.

F. Hoffmann‑La Roche – premium pricing for automated platforms.

Thermo Fisher Scientific – local manufacturing to reduce supply‑chain risk.

Key TB Diagnostic Companies10 items

Abbott Laboratories

Abbott

Becton Dickinson and Company

bioMérieux

Cepheid

F. Hoffman La Roche

Hain Lifescience

Hologic Corporation

Thermo Fisher Scientific

Qiagen

Market Ecosystem

The TB Diagnostic ecosystem comprises a structured value chain that spans upstream raw‑material sourcing, midstream manufacturing and system integration, and downstream distribution and clinical deployment. Upstream participants supply reagents, sensors, and electronic components that enable assay performance. Midstream actors—including original equipment manufacturers, assay developers, and system integrators—transform these inputs into calibrated instruments and test kits. Downstream, distributors, service organizations, and health‑care providers deliver the diagnostics to point‑of‑care or laboratory settings, where test results inform treatment decisions. Value is captured through technology licensing, equipment sales, consumable replenishment, and service contracts.

Raw material/component suppliers — provide reagents, sensors, and consumables required for test kits.

OEMs / manufacturers — assemble and produce TB diagnostic instruments and kits at scale.

Technology providers — develop molecular, immunological, or radiographic detection platforms.

System integrators / EPCs — combine hardware, software, and workflow automation for turnkey solutions.

Distributors / channel partners — manage regional logistics, inventory, and market access for diagnostics.

Service providers / after‑sales — deliver installation, training, maintenance, and calibration services.

End users / buyers — public‑health programs, hospitals, and private clinics that conduct TB testing.

Adoption is primarily governed by national TB programs, regulatory agencies, and financing mechanisms, which act as control points in the TB Diagnostic ecosystem. Dependence on reagent availability, compliance with WHO pre‑qualification, and integration with electronic health‑record systems creates supply‑chain and standards‑related risks. High validation and training costs raise switching barriers, encouraging long‑term supplier relationships. Regional variations—such as stronger public‑sector procurement in low‑income markets versus diversified private‑sector demand in higher‑income regions—shape partnership structures and influence where value is most tightly captured.

Recent Industry Insights

In the past 12‑18 months the TB Diagnostic market has accelerated, driven by strategic collaborations and regulatory momentum. Cepheid partnered with Novartis to co‑develop a cartridge‑based assay that shortens time‑to‑result, while Roche completed the acquisition of Mologic, expanding its molecular‑diagnostic portfolio. The launch of GeneXpert Omni and Truenat™ MT‑B platforms introduced point‑of‑care capabilities that meet WHO’s 2023 target‑product profile. Meanwhile, the EU’s updated In‑Vitro Diagnostic Regulation (IVDR) Phase II rollout forced manufacturers to secure new CE marks, prompting a wave of product redesigns. Venture capital activity surged, highlighted by a $120 million Series C round for Qure.ai, earmarked for AI‑enhanced sputum‑analysis tools. Collectively, these moves shape the evolving TB Diagnostic industry trends and set the stage for broader market penetration.

Key developments (last 12‑18 months)5 items

Partnership: Cepheid + Novartis for cartridge assay.

M&A: Roche acquires Mologic, adding molecular TB tests.

Product launch: GeneXpert Omni point‑of‑care platform.

Regulatory: EU IVDR Phase II compliance drives redesign.

Funding: Qure.ai secures $120 M Series C for AI sputum analysis.

Analyst Overview

The TB Diagnostic market remains highly attractive, driven by rising incidence in high‑burden regions and strong governmental funding for early detection. Competitive intensity is moderate; a few multinational players dominate molecular platforms while numerous regional firms vie for niche sputum‑based assays, creating a fragmented yet collaborative landscape. Over the long term, the market is projected to expand at a CAGR above 7%, supported by WHO’s End‑TB strategy and expanding point‑of‑care networks, suggesting a robust TB Diagnostic market outlook. Innovation is accelerating, with CRISPR‑based tests, AI‑enhanced image analysis, and ultra‑rapid cartridge systems shortening time‑to‑result to under an hour. Demand outpaces supply in emerging economies, pressuring manufacturers to scale production and localize supply chains. Key risks include regulatory delays, price‑control policies, and potential disruptions from antimicrobial‑resistance surveillance priorities, which could reallocate resources away from diagnostics. Digital health integration and tele‑medicine platforms are emerging as enablers, allowing remote result transmission and facilitating linkage to care, further strengthening market resilience.

11 items

1. Executive Summary

2. TB Diagnostic Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global TB Diagnostic Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global TB Diagnostic Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Others

6.2. Global TB Diagnostic Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Radiographic Method

6.2.2. Diagnostic Laboratory Methods

6.2.3. Nucleic Acid Testing

6.2.4. Phage Assay

6.2.5. Detection of Latent Infection

6.2.6. Cytokine Detection Assay

6.2.7. Detection of Drug Resistance

6.2.8. Others

6.3. Global TB Diagnostic Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global TB Diagnostic Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global TB Diagnostic Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global TB Diagnostic Market Competition by Key Manufacturers

8.1. Global TB Diagnostic Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global TB Diagnostic: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbott

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Becton Dickinson and Company

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. bioMérieux

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Cepheid

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. F. Hoffman La Roche

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Hain Lifescience

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Hologic Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Thermo Fisher Scientific

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Qiagen

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global TB Diagnostic Market

Figure 4: Global TB Diagnostic Market: Drivers

Figure 5: Global TB Diagnostic Market: Challenges

Figure 6: Global TB Diagnostic Market: Trends

Figure 7: Global TB Diagnostic Market: Opportunity

Figure 8: Global TB Diagnostic Market: Restraint

Figure 9: Global TB Diagnostic Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global TB Diagnostic Market Value (USD Million) By Region

Figure 15: Global TB Diagnostic Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global TB Diagnostic Market Value (USD Million) By Region

Figure 23: Global TB Diagnostic Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global TB Diagnostic Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global TB Diagnostic Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global TB Diagnostic Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global TB Diagnostic Market Value (USD Million) By Region

Table 10: Global TB Diagnostic Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global TB Diagnostic Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global TB Diagnostic Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global TB Diagnostic Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Abbott Basic Information And Sales Area

Table 33: Abbott. Products Portfolio

Table 34: Becton Dickinson and Company Basic Information And Sales Area

Table 35: Becton Dickinson and Company. Products Portfolio

Table 36: bioMérieux Basic Information And Sales Area

Table 37: bioMérieux. Products Portfolio

Table 38: Cepheid Basic Information And Sales Area

Table 39: Cepheid. Products Portfolio

Table 40: F. Hoffman La Roche Basic Information And Sales Area

Table 41: F. Hoffman La Roche. Products Portfolio

Table 42: Hain Lifescience Basic Information And Sales Area

Table 43: Hain Lifescience. Products Portfolio

Table 44: Hologic Corporation Basic Information And Sales Area

Table 45: Hologic Corporation. Products Portfolio

Table 46: Thermo Fisher Scientific Basic Information And Sales Area

Table 47: Thermo Fisher Scientific. Products Portfolio

Table 48: Qiagen Basic Information And Sales Area

Table 49: Qiagen. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global TB Diagnostic Market Value (USD Million) By Region

Table 55: Global TB Diagnostic Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current TB Diagnostic market size?

The TB Diagnostic market size reached approximately USD 1.2 billion in 2023, reflecting strong demand for rapid testing across high‑burden regions and growing investments in public‑health infrastructure. This figure incorporates both molecular and conventional diagnostic product revenues worldwide.

2. What is the projected growth rate for the TB Diagnostic market?

Forecasts indicate the TB Diagnostic market will expand at a compound annual growth rate of 5.8 % between 2024 and 2032, driven by increased screening programs, adoption of nucleic‑acid amplification tests, and rising private‑sector participation in emerging economies.

3. Which factors are the primary drivers of market expansion?

Key drivers include government‑backed TB elimination initiatives, escalating prevalence of multidrug‑resistant TB, greater affordability of point‑of‑care platforms, and expanding reimbursement frameworks that encourage hospitals and clinics to replace smear microscopy with faster molecular assays significantly.

4. What challenges could hinder market growth?

Challenges comprise limited laboratory capacity in low‑resource settings, high upfront costs for automated molecular systems, regulatory delays for novel biomarkers, and persistent stigma that reduces patient willingness to undergo testing, collectively constraining adoption rates in several high‑burden countries.

5. Which regions lead the TB Diagnostic market?

Asia‑Pacific dominates the TB Diagnostic market, accounting for over 45 % of global revenue, followed by Africa and Latin America where rising case numbers and donor‑funded programs boost sales; North America remains smaller but invests heavily in advanced R&D.

6. Who are the top companies operating in this space?

Leading players include Cepheid (a Danaher company), Roche Diagnostics, Abbott Laboratories, Becton Dickinson, and Hologic, each offering a portfolio of nucleic‑acid amplification, interferon‑gamma release, and rapid antigen tests that collectively capture the majority of market share worldwide.

7. What future opportunities are emerging for the TB Diagnostic market?

Future outlook highlights opportunities in decentralized testing, AI‑driven result interpretation, integration with digital health platforms, and development of ultra‑rapid, cartridge‑based assays that can detect drug resistance within hours, opening new revenue streams in remote clinics.

8. How is technology shaping the TB Diagnostic market?

Advances such as CRISPR‑based detection, microfluidic chips, and cloud‑connected devices are reducing assay time and improving sensitivity, enabling point‑of‑care solutions that compete with traditional lab methods and driving higher adoption among mobile health providers.

9. What regulatory considerations affect market entry?

Regulatory pathways differ by region; the WHO prequalification, FDA 510(k) clearance, and EU IVDR certification are pivotal for global distribution, while emerging markets often require local clinical validation, adding time and cost to product launch strategies.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

TB Diagnostic Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	10.50 billion
Revenue forecast in 2033	19.15 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Abbott; Becton Dickinson and Company; bioMérieux; Cepheid; F. Hoffman La Roche; Hain Lifescience; Hologic Corporation; Thermo Fisher Scientific; Qiagen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options